What kind of monitoring is essential to prevent INH-related complications?

Monitoring liver function tests is essential for patients on isoniazid (INH) therapy because INH can be hepatotoxic, leading to liver damage in some individuals. Hepatotoxicity is a significant risk associated with INH, particularly in patients with pre-existing liver conditions, those who consume alcohol, or individuals who are taking other medications that may affect liver function.

Routine liver function tests typically include assessments of serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), along with bilirubin levels. Regular monitoring allows healthcare providers to detect any signs of liver injury early, enabling timely interventions, such as discontinuation of the medication or modification of treatment plans.

While options such as vision tests, psychological assessments, and physical therapy evaluations may be relevant in certain healthcare contexts, they do not specifically address the most critical complications associated with INH therapy. Thus, the focus on liver function tests is crucial to ensuring patient safety and managing the potential risks tied to INH treatment.